164 related articles for article (PubMed ID: 11659718)
21. Observational research on the electronic superhighway; Problems on the Internet: a lawyer's perspective; The networker's perspective; Bioethics perspective; User's perspective.
Rosenoer J; Isaacs S; Macklin R; Silverman S
Ethics Behav; 1995; 5(1):105-18. PubMed ID: 11654167
[No Abstract] [Full Text] [Related]
22. Ethics of clinical trials for research ethics boards: proceedings of a national workshop.
National Council on Bioethics in Human Research (Canada)
NCBHR Commun; 1991; 2(2):4-23. PubMed ID: 11659919
[No Abstract] [Full Text] [Related]
23. A prostate researcher tested firm's product -- and sat on its board.
Burton TM
Wall St J (East Ed); 1998 Mar; ():A1, A8. PubMed ID: 11648093
[No Abstract] [Full Text] [Related]
24. Ethical oxymora for risk assessment practitioners.
Greenberg MR; Spiro H; McIntyre R
Account Res; 1991; 1(4):245-57. PubMed ID: 11651458
[No Abstract] [Full Text] [Related]
25. The case for per patient payments.
Lewis JP
IRB; 1988; 10(5):9. PubMed ID: 11650075
[No Abstract] [Full Text] [Related]
26. Is post-marketing drug follow-up research or advertising?
Weiss GB; Winslade WJ
IRB; 1987; 9(4):10-1. PubMed ID: 11649947
[No Abstract] [Full Text] [Related]
27. Case vignette: inside information.
Kobrick FR; Rodwin MA; VandenBos GR
Ethics Behav; 1993; 3(1):135-47. PubMed ID: 11653081
[TBL] [Abstract][Full Text] [Related]
28. Canadian panel calls for review of drug-trial confidentiality agreements.
Kondro W
Lancet; 1998 Dec 19-26; 352(9145):1996. PubMed ID: 11656958
[No Abstract] [Full Text] [Related]
29. A national research ethics committee?
Alderson P
Bull Med Ethics; 1995 Apr; No. 107():13-6. PubMed ID: 11654315
[No Abstract] [Full Text] [Related]
30. Perspectives of protocol reviewers.
Moline ML; Aisen MW
J Calif Alliance Ment Ill; 1994; 5(1):59-60. PubMed ID: 11653327
[No Abstract] [Full Text] [Related]
31. Ethical aspect of research involving elderly subjects.
Fletcher JC
J Clin Ethics; 1990; 1(4):285-6. PubMed ID: 11642836
[No Abstract] [Full Text] [Related]
32. Deception methods in psychology: have they changed in 23 years?
Sieber JE; Iannuzzo R; Rodriguez B
Ethics Behav; 1995; 5(1):67-85. PubMed ID: 11654171
[TBL] [Abstract][Full Text] [Related]
33. Drug trials hide conflicts for doctors.
Eichenwald K; Kolata G
N Y Times Web; 1999 May; ():1, 34. PubMed ID: 11648114
[No Abstract] [Full Text] [Related]
34. IRBs and pharmaceutical company funding of research.
Jellinek MS; Levine RJ
IRB; 1982 Oct; 4(8):9-10. PubMed ID: 11651693
[No Abstract] [Full Text] [Related]
35. A question of consent.
Lenox-Smith I; Brahams D
Practitioner; 1983 Jan; 227(1375):18. PubMed ID: 11643990
[No Abstract] [Full Text] [Related]
36. Parafraud in biology.
Hillman H
Sci Eng Ethics; 1997 Apr; 3(2):121-36. PubMed ID: 11657883
[No Abstract] [Full Text] [Related]
37. Testing new drugs: joining a study can be rewarding -- but risky How to find -- and survive -- a clinical trial.
Consum Rep; 1998 Dec; 63(12):64-5. PubMed ID: 11660639
[No Abstract] [Full Text] [Related]
38. The regulation of human experimentation in the United States--a personal odyssey.
Katz J
IRB; 1987; 9(1):1-6. PubMed ID: 11649890
[No Abstract] [Full Text] [Related]
39. In search of funding: the clinical investigator and the drug company; Commentary: why researchers need not be demoralized.
Siris ES; Burrell CD
IRB; 1983; 5(6):1-5. PubMed ID: 11649526
[No Abstract] [Full Text] [Related]
40. Fatal accident inquiry: death during research.
Hamilton P
Bull Med Ethics; 1997 Aug; No. 130():22-4. PubMed ID: 11657185
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
